{"id":"https://openalex.org/W28971453","doi":null,"title":"177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours : Dosimetry-Based Therapy Planning and Outcome","display_name":"177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours : Dosimetry-Based Therapy Planning and Outcome","alternate_titles":[],"publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W28971453","mag":"28971453"},"language":"en","primary_location":{"id":"pmh:oai:DiVA.org:uu-183417","doi":null,"is_oa":true,"landing_page_url":"http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183417","pdf_url":null,"source":{"id":"https://openalex.org/S4306400653","display_name":"DiVA (Digitala Vetenskapliga Arkivet)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/doctoralThesis"},"parent_works":[],"lineage":["https://openalex.org/W28971453"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183417","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090273747","display_name":"Ulrike Garske\u2010Rom\u00e1n","orcid":"https://orcid.org/0000-0002-5571-5041","observed_orcids":["https://orcid.org/0000-0002-5571-5041"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ulrike Garske\u2013Rom\u00e1n","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5571-5041","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5090273747"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.5853999853134155,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.5853999853134155,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.4043000042438507,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10522","display_name":"Medical Imaging Techniques and Applications","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/peptide-receptor-radionuclide-therapy","display_name":"peptide receptor radionuclide therapy","score":0.9929999709129333},{"id":"https://openalex.org/keywords/neuroendocrine-tumors","display_name":"neuroendocrine tumors","score":0.9829999804496765},{"id":"https://openalex.org/keywords/somatostatin-receptors","display_name":"somatostatin receptors","score":0.7110000252723694},{"id":"https://openalex.org/keywords/bone-marrow-dose","display_name":"bone marrow dose","score":0.7319999933242798},{"id":"https://openalex.org/keywords/kidney-dose","display_name":"kidney dose","score":0.9300000071525574},{"id":"https://openalex.org/keywords/effective-half-life","display_name":"effective half-life","score":0.6809999942779541},{"id":"https://openalex.org/keywords/bronchial-carcinoid","display_name":"bronchial carcinoid","score":0.9779999852180481},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.859000027179718},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.44600000977516174}],"concepts":[{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.9257289171218872},{"id":"https://openalex.org/C2779931791","wikidata":"https://www.wikidata.org/wiki/Q161515","display_name":"DOTA","level":3,"score":0.6109717488288879},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5743528008460999},{"id":"https://openalex.org/C19527891","wikidata":"https://www.wikidata.org/wiki/Q1120908","display_name":"Medical physics","level":1,"score":0.4644816815853119},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.45918458700180054},{"id":"https://openalex.org/C75088862","wikidata":"https://www.wikidata.org/wiki/Q2291081","display_name":"Dosimetry","level":2,"score":0.45877349376678467},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.4395180344581604},{"id":"https://openalex.org/C201645570","wikidata":"https://www.wikidata.org/wiki/Q830637","display_name":"Radiation treatment planning","level":3,"score":0.43482571840286255},{"id":"https://openalex.org/C3018694869","wikidata":"https://www.wikidata.org/wiki/Q927316","display_name":"Radioiodine therapy","level":4,"score":0.4346857964992523},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1598253846168518},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.12057334184646606},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.08106750249862671},{"id":"https://openalex.org/C197404232","wikidata":"https://www.wikidata.org/wiki/Q319827","display_name":"Chelation","level":2,"score":0.0},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:DiVA.org:uu-183417","doi":null,"is_oa":true,"landing_page_url":"http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183417","pdf_url":null,"source":{"id":"https://openalex.org/S4306400653","display_name":"DiVA (Digitala Vetenskapliga Arkivet)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/doctoralThesis"},{"id":"mag:28971453","doi":null,"is_oa":false,"landing_page_url":"https://uu.diva-portal.org/smash/record.jsf?pid=diva2:562732","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:DiVA.org:uu-183417","doi":null,"is_oa":true,"landing_page_url":"http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-183417","pdf_url":null,"source":{"id":"https://openalex.org/S4306400653","display_name":"DiVA (Digitala Vetenskapliga Arkivet)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/doctoralThesis"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2789923927","https://openalex.org/W1983680048","https://openalex.org/W136638838","https://openalex.org/W2900733241","https://openalex.org/W2297869264","https://openalex.org/W636431968","https://openalex.org/W2017183061","https://openalex.org/W3166545880","https://openalex.org/W4407051260","https://openalex.org/W2993353311"],"abstract_inverted_index":{"Peptide":[0],"receptor":[1],"radionuclide":[2,321],"therapy":[3,101,245,322],"for":[4,108,115,330],"the":[5,26,73,98,109,127,131,145,150,157,164,173,181,201,212,218,224],"internal":[6],"radiation":[7,43],"of":[8,25,41,64,80,144,194,214,243,283],"neuroendocrine":[9,252,285,334],"tumours":[10,49,253,292,335],"expressing":[11,336],"somatostatin":[12,337],"receptors":[13],"has":[14,68],"made":[15],"great":[16],"advances":[17],"and":[18,33,48,61,97,160,254,303],"offers":[19],"promising":[20],"results.":[21],"177Lu-DOTA-octreotate":[22,209,324],"is":[23,325],"one":[24],"most":[27,139],"widely":[28,69],"used":[29],"radiopeptides,":[30],"but":[31],"kidneys":[32,99,219],"bone":[34,95,110,225],"marrow":[35,96,111],"are":[36],"organs":[37,47,117],"at":[38,184],"risk.":[39],"Methods":[40],"measuring":[42],"doses":[44,93],"to":[45,84,90,94,217,223,239,259,275,277],"at-risk":[46],"(dosimetry)":[50],"on":[51,123,180],"an":[52],"individual":[53],"patient":[54],"basis":[55],"have":[56,260],"been":[57,70,120],"regarded":[58],"as":[59,72],"impracticable":[60],"a":[62,86,281,315,326],"maximum":[63],"4":[65,203,233],"treatment":[66,74,204,241,328],"cycles":[67,205],"accepted":[71],"standard":[75,202],"instead.":[76],"The":[77,189,235],"first":[78,158],"aim":[79,237],"this":[81,264,301],"thesis":[82,133],"was":[83,112,135,170,238,288],"establish":[85],"clinically":[87],"feasible":[88],"protocol":[89,107],"calculate":[91],"absorbed":[92,174],"during":[100,156],"with":[102,163,206,246,249,263,293,300,323,332],"177Lu-DOTA-octreotate.":[103,247],"A":[104],"new":[105],"dosimetry":[106,155],"described.":[113],"Dosimetry":[114],"solid":[116],"had":[118],"previously":[119,267],"described":[121],"based":[122,179],"3-dimensional":[124],"imaging":[125],"by":[126],"research":[128],"group.":[129],"In":[130],"current":[132],"it":[134,162,169,287],"demonstrated":[136],"that":[137,172,192,290,304],"in":[138,149,166,280,310,314],"patients":[140,196,331],"only":[141],"minor":[142],"changes":[143],"effective":[146,317],"half-life":[147],"occurred":[148],"kidneys.":[151],"By":[152],"performing":[153],"complete":[154],"cycle":[159],"comparing":[161],"uptake":[165],"later":[167,311],"cycles,":[168,312],"shown":[171,258,289],"dose":[175],"can":[176,296,308],"be":[177,273,298],"cal-culated":[178],"activity":[182],"concentration":[183],"24":[185],"hours":[186],"after":[187],"therapy.":[188],"study":[190],"concluded":[191],"50%":[193],"all":[195],"could":[197,272],"receive":[198],"more":[199,316],"than":[200,232,266],"7.4":[207],"GBq":[208],"without":[210],"passing":[211],"limit":[213],"23":[215],"Gray":[216,222],"or":[220],"2":[221],"marrow,":[226],"whereas":[227],"20%":[228],"would":[229],"tolerate":[230],"fewer":[231],"cycles.":[234],"second":[236],"describe":[240],"outcomes":[242],"dosimetry-guided":[244],"Patients":[248],"metastasized":[250],"colorectal":[251],"bronchial":[255],"carcinoids":[256],"were":[257],"longer":[261],"survival":[262],"method":[265,302],"reported.":[268],"Morphological":[269],"tumour":[270],"response":[271],"correlated":[274],"time":[276],"progression.":[278],"Furthermore,":[279],"case":[282],"low-differentiated":[284],"cancer":[286],"large":[291],"high":[294],"proliferation":[295],"also":[297],"treated":[299],"tumour-to-risk":[305],"organ":[306],"ratios":[307],"improve":[309],"resulting":[313],"treatment.":[318],"Dosimetry-guided,":[319],"fractionated":[320],"valuable":[327],"option":[329],"advanced":[333],"receptors.":[338]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W28971453","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
